NRG-GY036

Official Title

A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY

Study Purpose

To study if the use of Olaparib for one year keeps your ovarian cancer from growing or returning as well as the usual approach of two years.

Diagnosis

Ovarian cancer with either BRCA mutation (1 or 2), or homologous recombination deficiency (HRD+).

Eligibility

Newly diagnosed Stage III or IV ovarian cancer after completion of first line platinum based therapy and cytoreductive surgery.

Intervention

Oral Olaparib for 1 year vs 2 years. (Bevacizumab may be given x 1 year at physician’s discretion.)